Pathology in Italy: Prostate Cancer

  • December 2010
  • -
  • Global Data

The report is an essential source of information and analysis on the Italian prostate cancer therapeutics industry . The report provides comprehensive data on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the major industry developments shaping and driving the Italian prostate cancer therapeutics industry, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing industry leaders. The report provides valuable insights into the new product development within the global prostate cancer segment . It quantifies the unmet need in the Italian prostate cancer therapeutics industry, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

Research Scope

The scope of the report includes:
- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized Italian prostate cancer therapeutics industry revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, projection for 11 years to 2020.
- Insightful review of the key market drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales projections .
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales projection .
- Analysis of unmet need in the industry and target product profiles including opportunity for target products.
- Technology trends analytic framework to assess the strength of the pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, industry ing rights and launch analysis.
- Analysis of the current and future industry competition in the Italian Prostate Cancer therapeutics industry . Firms profiles including business description, financial overview and SWOT analysis. Key future industry players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics industry . Merger and Acquisition (M&A analysis) which includes Merger and Acquisition deals by size and geography.
- Strategic assessment of the industry through industry impact analysis, future industry scenario and industry player analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics industry in Italy.

Why Should You Get This Report?

The report will enhance your decision making capability. It will allow you to:
- Develop business strategies and perform superior industry quantification analysis by
- Understanding the trends shaping and driving the Italian prostate cancer therapeutics industry .
- Understanding the treatment preferences of physicians for each disease state and across treatment flow.
- Accessing industry sizing projections and quantified growth opportunities in the Italian prostate cancer therapeutics industry up to 2020.
- Quantifying the patient population in the Italian to better design product pricing and launch plans.
- Drive revenues, formulate effective sales and industry ing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently industry ed products.
- Identifying industry entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in the industry by understanding the strengths and weaknesses of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.
- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
- Track drug sales in the Italian prostate cancer therapeutics industry from 2001 to 2020.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the Italian prostate cancer therapeutics industry landscape? Identify, understand and decide.

Table Of Contents

1 Table of contents 3
I. 1 List of Data tables 6
I. 2 List of Charts 7
2 Disease Data 9
II. 1 Overview 9
II. 1.1 TNM (Tumor, Nodes, Metastasis) Staging System 9
II. 1.2 Jewett-Whitmore system 10
II. 2 Epidemiology 11
II. 3 Etiology 11
II. 4 Symptoms 11
II. 4.1 Localized or Locally Advanced Prostate Cancer 11
II. 4.2 Metastatic Prostate Cancer 12
II. 5 Diagnosis 12
II. 5.1 Digital Rectal Examination 12
II. 5.2 Prostate Specific Antigen Test 13
II. 5.3 Transrectal Ultrasound 13
II. 5.4 Prostate Biopsy 13
II. 6 Pathology 14
II. 6.1 Grading 14
II. 7 Treatment 14
II. 7.1 Watchful Waiting 14
II. 7.2 Radiation therapy 14
II. 7.3 Surgery 15
II. 7.4 Hormone therapy 16
II. 7.5 Chemotherapy Options 17
II. 7.6 Other Treatments Being Studied 17
II. 8 Treatment Guidelines 18

III March ket Characterization 19
III. 1 Italy 19
III. 1.1 March ket Size 19
III. 1.2 Drivers and Barriers 25
III. 1.3 Impact on the March ket 27
III. 1.4 Forecasted data s 28
III. 1.5 Drug Sales 34
III. 1.6 Pricing and Reimbursements 38

IV Competitor Assessment 39
IV. 1 Strategic Competitor Assessment 39
IV. 1.1 Overview 39
IV. 1.2 Benchmarking 39
IV. 1.3 Current Competitor Assessment 43
IV. 2 Launch Analysis and Sales Forecasted data s 45
IV. 3 Product Profiles 46
IV. 3.1 Taxotere (docetaxel) 47
IV. 3.2 Casodex (Bicalutamide) 51
IV. 3.3 Zoladex (Goserelin) 57
IV. 3.4 Eligard (leuprolide acetate) 59
IV. 3.5 Firmagon (degarelix) 64
IV. 3.6 November antrone (Mitoxantrone hydrochloride) 66
IV. 3.7 Emcyt (estramustine) 69
IV. 3.8 Trelstar (triptorelin) 71
IV. 3.9 Eulexin 72
IV. 3.10 Delestrogen 74
IV. 3.11 Gynodiol 76
IV. 3.12 Estrace tablet 77
IV. 3.13 Tace 78
IV. 3.14 Nilandrone 79
IV. 3.15 Premarin 80
IV. 3.16 Sales Forecasted data for Trelstar, December apeptyl, Gonapeptyl, Flutamide, Estradiol 81

V Pipeline Assessment 82
V. 1 Overview 82
V. 2 Pipeline Analysis by Phase of Development 83
V. 3 Pipeline by Mechanism of Action 84
V. 4 Strategic Pipeline Assessment 85
V. 4.1 Technology Trends Analytical Framework 85
V. 5 Trends in Prostate Cancer Pipeline 86
V. 5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying November el Targets for Prostate Cancer Drugs 86
V. 5.2 Molecules with November el Mechanism of Action Strengthening Prostate Cancer Pipeline 86
V. 5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 87
V. 6 Partners in Research and Development 87
V. 6.1 Licensing Agreements by Phase of Development 88
V. 6.2 Licensing Agreements by Geography 91
V. 6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 91
V. 7 Most Promising Drugs’ Profiles 92
V. 7.1 Provenge (sipuleucel-T) 94
V. 7.2 Jevtana (cabazitaxel) 96
V. 7.3 Aflibercept (VEGF Trap) 97
V. 7.4 Ipilimumab 100
V. 7.5 Abiraterone Acetate (CB7630) 102
V. 7.6 Zibotentan (ZD4054) 105
V. 7.7 Sprycel (dasatinib) 108
V. 7.8 MDV3100 110
V. 8 Prostate Cancer Pipeline - Pre-clinical Phase 112
V. 9 Prostate Cancer Pipeline - Phase I 114
V. 10 Prostate Cancer Pipeline - Phase II 117
V. 11 Prostate Cancer Pipeline - Phase III 125
V. 12 Key Takeaway 127

VI Unmet Need and Target Product Profile 128
VI. 1 Unmet Need 130
VI. 1.1 Hormone-independent Metastatic Prostate Cancer Therapy 131
VI. 1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 132
VI. 2 Opportunity for Target Product 132
VI. 3 Target Product Profile 134
VI. 3.1 Ideal Characteristics 134
VI. 3.2 Target Product Description 135
VI. 4 Key Takeaway 135

VII Strategic Assessment 136
VII. 1 Key Events Impacting the Future March ket 136
VII. 2 March ket Impact Analysis 137
VII. 3 Future March ket Scenario 137
VII. 4 Firms Analysis 139
VII. 4.1 March ket Leadership 139
VII. 4.2 Future Players in the March ket 139
VII. 5 Key Takeaway 140

VIII Company Profiles 141
VIII. 1 Sanofi-aventis 141
VIII. 1.1 Business Overview 141
VIII. 1.2 Financial Overview 143
VIII. 1.3 SWOT 143
VIII. 1.4 Oncology Focus 148
VIII. 2 Pfizer Inc. 149
VIII. 2.1 Business Overview 149
VIII. 2.2 Financial Overview 150
VIII. 2.3 SWOT 150
VIII. 2.4 Oncology Focus 157
VIII. 3 AstraZeneca 159
VIII. 3.1 Business Overview 159
VIII. 3.2 Financial Overview 160
VIII. 3.3 SWOT 161
VIII. 3.4 Oncology Focus 165
VIII. 4 Bristol-Myers Squibb 167
VIII. 4.1 Business Overview 167
VIII. 4.2 Financial Overview 168
VIII. 4.3 SWOT 168
VIII. 4.4 Oncology Focus 174
VIII. 5 Medivation 176
VIII. 5.1 Business Overview 176
VIII. 5.2 SWOT 176
VIII. 5.3 Oncology Focus 179
VIII. 6 Takeda Pharmaceuticals 180
VIII. 6.1 Business Overview 180
VIII. 6.2 SWOT 180
VIII. 7 Dendreon Corporation 182
VIII. 7.1 Business Overview 182
VIII. 7.2 SWOT 182
VIII. 8 Johnson and Johnson 185
VIII. 8.1 Business Overview 185
VIII. 8.2 SWOT 187
VIII. 8.3 Oncology Focus 193
VIII. 9 Auron Healthcare GmbH 194
VIII. 9.1 Business Overview 194
VIII. 10 Oncogenex Pharmaceuticals, Inc. 194
VIII. 10.1 Business Overview 194
VIII. 11 Agennix AG 194
VIII. 11.1 Business Overview 194
VIII. 12 GTx, Inc. 195
VIII. 12.1 Business Overview 195
VIII. 13 GlaxoSmithKline plc. 195
VIII. 13.1 Business Overview 195
VIII. 13.2 Financial Overview 196
VIII. 13.3 SWOT 196
VIII. 13.4 Oncology Focus 202

IX MandA Analysis 204
IX. 1 Key Highlights 204
IX. 2 Key Deals’ Analysis 206
IX. 2.1 Johnson and Johnson Takes Over Cougar Biotechnology 206
IX. 2.2 Endo Pharmaceuticals Takes Over Indevus Pharmaceuticals 206
IX. 2.3 Tolmar Holding Takes Over QLT USA from QLT 206
IX. 2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 206
IX. 2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly and Co. 206
IX. 2.6 Quest PharmaTech Takes Over Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 207
IX. 2.7 VaxOnco Takes Over Rights to Onyvax-P Cell Vaccine From Onyvax 207
IX. 2.8 GPC Biotech Merges with Agennix 207
IX. 2.9 Eli Lilly Takes Over ImClone 207
IX. 2.10 BBM Holdings Takes Over YM BioSciences 207
IX. 2.11 Sagent Pharmaceuticals Takes Over Injectable Generic Drug Applications of Spectrum Pharmaceuticals 208
IX. 3 Merger and Acquisition Deals by Geography 208
IX. 4 Merger and Acquisition Deals by Deal Size 209

X Expert Opinion 210
X. 1 Italy 210

XI Appendix 211
XI. 1 March ket Definitions 211
XI. 2 Abbreviations 211
XI. 3 Research Methodology 213
XI. 3.1 Coverage 213
XI. 3.2 Secondary Research 214
XI. 3.3 Forecasted data ing 214
XI. 3.4 Primary Research 217
XI. 3.5 Expert Panel validation 217
XI. 3.6 Contact Us 217
XI. 4 Disclaimer 217
XI. 5 Sources 2181.1 List of Data tables
Data table 1: Prostate Cancer Therapeutics March ket, Global, Staging of the Prostate Cancer, 2010 10
Data table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 13
Data table 3: Prostate Cancer Therapeutics March ket, Italy, Sales Value (USD Million), from 2001 to 2009 19
Data table 4: Prostate Cancer Therapeutics March ket, Italy, Annual Cost of Therapy ($), from 2001 to 2009 20
Data table 5: Prostate Cancer Therapeutics March ket, Italy, Patient Volume (’000s), from 2001 to 2009 22
Data table 6: Prostate Cancer Therapeutics March ket, Italy, Treatment Usage Patterns (’000s), from 2001 to 2009 23
Data table 7: Prostate Cancer Therapeutics March ket, Italy, Sales Value (USD Million), from 2009 to 2020 28
Data table 8: Prostate Cancer Therapeutics March ket, Italy, Annual Cost of Therapy ($), from 2009 to 2020 29
Data table 9: Prostate Cancer Therapeutics March ket, Italy, Patient Volume (’000s), from 2009 to 2020 30
Data table 10: Prostate Cancer Therapeutics March ket, Italy, Treatment Usage Patterns (’000s), from 2009 to 2020 31
Data table 11: Prostate Cancer Therapeutics March ket, Italy, Hormone-Refractory Prostate Cancer Drug Sales (USD Million), from 2001 to 2010 35
Data table 12: Prostate Cancer Therapeutics March ket, Italy, Hormone-Refractory Prostate Cancer Drug Sales (USD Million), from 2011 to 2020 35
Data table 13: Prostate Cancer Therapeutics March ket, Italy, Hormone-Dependent Prostate Cancer Drug Sales (USD Million), from 2001 to 2010 37
Data table 14: Prostate Cancer Therapeutics March ket, Italy, Hormone-Dependent Prostate Cancer Drug Sales (USD Million), from 2011 to 2020 37
Data table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 40
Data table 16: Prostate Cancer, Global, Chemotherapy, Safety Company Profile: Standard Care Treatment, 2010 41
Data table 17: Prostate Cancer, Global, Hormone Therapy, Safety Company Profile: Standard Care Treatment, 2010 42
Data table 18: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 52
Data table 19: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 60
Data table 20: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 61
Data table 21: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 62
Data table 22: Prostate Cancer, Global, Licensing Agreements, from 2009 to 2010 90
Data table 23: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 92
Data table 24: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 92
Data table 25: Prostate Cancer, Global, Pre-clinical Phase Pipeline, 2010 112
Data table 26: Prostate Cancer, Global, Phase I Pipeline, 2010 114
Data table 27: Prostate Cancer, Global, Phase II Pipeline, 2010 117
Data table 28: Prostate Cancer, Global, Phase III Pipeline, 2010 125
Data table 29: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the March ket, 2010 134
Data table 30: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the March ket, 2010 135
Data table 31: Prostate Cancer, Johnson and Johnson, Oncology Late Stage Pipeline by Indication, 2010 193
Data table 32: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 194
Data table 33: Prostate Cancer, Global, Merger and Acquisition Deals by Geography, 2010 2041.2

List of Figures

Chart 1: Prostate Cancer Therapeutics March ket, Global, Treatment Guidelines, 2010 18
Chart 2: Prostate Cancer Therapeutics March ket, Italy, Sales Value (USD Million), from 2001 to 2009 19
Chart 3: Prostate Cancer Therapeutics March ket, Italy, Annual Cost of Therapy ($), from 2001 to 2009 20
Chart 4: Prostate Cancer Therapeutics March ket, Italy, Patient Volume (’000s), from 2001 to 2009 22
Chart 5: Prostate Cancer Therapeutics March ket, Italy, Treatment Usage Patterns (’000s), from 2001 to 2009 23
Chart 6: Prostate Cancer Therapeutics March ket, Italy, March ket Drivers and Restraints, 2009 25
Chart 7: Prostate Cancer Therapeutics March ket, Italy, Historical data al Events Impact on the March ket, 2010 27
Chart 8: Prostate Cancer Therapeutics March ket, Italy, Sales Value (USD Million), from 2009 to 2020 28
Chart 9: Prostate Cancer Therapeutics March ket, Italy, Annual Cost of Therapy ($), from 2009 to 2020 29
Chart 10: Prostate Cancer Therapeutics March ket, Italy, Patient Volume (’000s), from 2009 to 2020 30
Chart 11: Prostate Cancer Therapeutics March ket, Italy, Treatment Usage Patterns (’000s), from 2009 to 2020 31
Chart 12: Prostate Cancer Therapeutics March ket, Italy, Future March ket Drivers and Restraints, from 2009 to 2020 33
Chart 13: Prostate Cancer Therapeutics March ket, Italy, Hormone-refractory Prostate Cancer Drug Sales (USD Million), from 2001 to 2020 34
Chart 14: Prostate Cancer Therapeutics March ket, Italy, Hormone-Dependent Prostate Cancer Drug Sales (USD Million), from 2001 to 2020 36
Chart 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major March keted Drugs, Chemotherapy Drugs, 2010 43
Chart 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major March keted Drugs, Hormone Therapy Drugs, 2010 44
Chart 17: Prostate Cancer Therapeutics March ket, Italy, Sales Forecasted data by Therapies, from 2001 to 2020 45
Chart 18: Prostate Cancer, Global, Taxotere, Chemical Structure 47
Chart 19: Prostate Cancer, Global, Taxotere, LCM Activities, from 2004 to 2010 49
Chart 20: Prostate Cancer, Italy, Taxotere, Sales (USD Million), from 2004 to 2020 50
Chart 21: Prostate Cancer, Global, Casodex, Chemical Structure 51
Chart 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 55
Chart 23: Prostate Cancer, Italy, Casodex, Sales (USD Million), 1995-2020 56
Chart 24: Prostate Cancer, Global, Zoladex, Chemical Structure 57
Chart 25: Prostate Cancer, Italy, Zoladex, Sales Forecasted data (USD Million), 1998-2020 58
Chart 26: Prostate Cancer, Global, Eligard, Chemical Structure 59
Chart 27: Prostate Cancer, Italy, Leuprolide (Eligard), Sales Forecasted data (USD Million), from 2006 to 2020 63
Chart 28: Prostate Cancer, Global, Firmagon, Chemical Structure 64
Chart 29: Prostate Cancer, Italy, Firmagon, Sales Forecasted data (USD Million), from 2009 to 2020 65
Chart 30: Prostate Cancer, Global, November atrone, Chemical Structure 66
Chart 31: Prostate Cancer, Italy, Mitoxantrone, Sales Forecasted data (USD Million), from 2001 to 2020 68
Chart 32: Prostate Cancer, Global, Emcyt, Chemical Structure 69
Chart 33: Prostate Cancer, Italy, Estramustine, Sales Forecasted data (USD Million), from 2001 to 2020 70
Chart 34: Prostate Cancer, Global, Trelstar, Chemical Structure 71
Chart 35: Prostate Cancer, Global, Eulexin, Chemical Structure 72
Chart 36: Prostate Cancer, Global, Delestrogen, Chemical Structure 74
Chart 37: Prostate Cancer, Global, Gynodiol, Chemical Structure 76
Chart 38: Prostate Cancer, Global, Estrace, Chemical Structure 77
Chart 39: Prostate Cancer, Global, Tace, Chemical Structure 78
Chart 40: Prostate Cancer, Global, Nilandrone, Chemical Structure 79
Chart 41: Prostate Cancer, Global, Premarin, Chemical Structure 80
Chart 42: Prostate Cancer, Italy, Combined sales of Trelstar, December apeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecasted data (USD Million), from 2001 to 2020 81
Chart 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 82
Chart 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 83
Chart 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 84
Chart 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 85
Chart 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 86
Chart 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, from 2009 to 2010 88
Chart 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 91
Chart 50: Prostate Cancer, Italy, Provenge, Sales Forecasted data (USD Million), from 2012 to 2020 95
Chart 51: Prostate Cancer, Italy, Jevtana, Sales Forecasted data (USD Million), from 2011 to 2020 97
Chart 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 98
Chart 53: Prostate Cancer, Italy, Aflibercept, Sales Forecasted data (USD Million), 2014-2020 99
Chart 54: Prostate Cancer, Italy, Ipilimumab, Sales Forecasted data (USD Million), 2014-2020 101
Chart 55: Prostate Cancer, Global, Abiraterone, Chemical Structure 102
Chart 56: Prostate Cancer, Italy, Abiraterone, Sales Forecasted data (USD Million), 2013-2020 104
Chart 57: Prostate Cancer, Global, Zibotentan, Chemical Structure 105
Chart 58: Prostate Cancer, Italy, Zibotentan, Sales Forecasted data (USD Million), 2013-2020 107
Chart 59: Prostate Cancer, Italy, Sprycel, Sales Forecasted data (USD Million), 2013-2020 109
Chart 60: Prostate Cancer, Global, MDV3100, Chemical Structure 110
Chart 61: Prostate Cancer, Italy, MDV3100, Sales Forecasted data (USD Million), 2013-2020 111
Chart 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 128
Chart 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 129
Chart 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 129
Chart 65: Prostate Cancer, Italy, Prostate Cancer, Opportunity and Unmet Need, 2010 130
Chart 66: Prostate Cancer, Italy, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 133
Chart 67: Prostate Cancer, Italy, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 133
Chart 68: Prostate Cancer, Global, Key Events Impacting the Future March ket 136
Chart 69: Prostate Cancer, Italy, Implications for Future March ket Competition, 2010 137
Chart 70: Prostate Cancer, Global, Future Players in the March ket, 2010 139
Chart 71:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 141
Chart 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 142
Chart 73: Prostate Cancer, Global, Sanofi-aventis, SWOT, 2010 143
Chart 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 148
Chart 75: Prostate Cancer, Global, Pfizer, SWOT 2010 150
Chart 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 157
Chart 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 158
Chart 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 160
Chart 79: Prostate Cancer, Global, AstraZeneca, SWOT 2010 161
Chart 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 165
Chart 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 166
Chart 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 166
Chart 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 167
Chart 84: Prostate Cancer, Global, Firms Bristol-Myers Squibb, SWOT, 2010 168
Chart 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 174
Chart 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 175
Chart 87: Prostate Cancer, Global, Medivation, SWOT 2010 176
Chart 88: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT 2010 180
Chart 89: Prostate Cancer, Global, Dendreon Corporation, SWOT 2010 182
Chart 90: Prostate Cancer, Global, Johnson and Johnson, SWOT 2010 187
Chart 91: Prostate Cancer, Johnson and Johnson, Late Stage Pipeline by Therapy Area, 2010 193
Chart 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT 2010 196
Chart 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 202
Chart 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 203
Chart 95: Prostate Cancer, Global, Merger and Acquisition Deals by Geography of Target Firms, 2010 208
Chart 96: Prostate Cancer, Global, Merger and Acquisition Deals by Deal Size, 2010 209
Chart 97: Prostate Cancer, Italy, Key Data Inputs from KOL Interviews, 2010 210
Chart 99: GlobalData March ket Forecasted data ing Model 216

Companies mentioned
Sanofi-aventis
Pfizer Inc.
AstraZeneca
Bristol-Myers Squibb
Medivation
Takeda Pharmaceuticals
Dendreon Corporation
Johnson and Johnson
Auron Healthcare GmbH
Oncogenex Pharmaceuticals, Inc.
Agennix AG
GTx, Inc.
GlaxoSmithKline plc.

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Diagnostics and Therapeutics for HIV: Global Markets

Diagnostics and Therapeutics for HIV: Global Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

STUDY GOALS AND OBJECTIVES The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the treatment, testing ...

JAK and PI3K Signaling Pathway Markets

JAK and PI3K Signaling Pathway Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion ...

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.